Mechanism for Exercise to Delay Cardiac Aging

Health Behavior Clinical Trial

Official title:

The αKlotho Protein-mediated NLRP3/Caspase-1/GSDMD Pathway Counteracts Myocardial Stunning: a Novel Mechanism for Exercise to Delay Cardiac Aging

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06031675
• Other study ID #: K0001
• Status: Completed
• Start date: May 12, 2023
• Est. completion date: September 1, 2023

Study information

• Verified date: September 2023
• Source: Sun Yat-sen University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The goal of this clinicaltrial is to assess and compare isokinetic performance, surface electromyography, laboratory parameters, and cardiorespiratory function both before and after engaging in vigorous intermittent lifestyle physical activity(VILPA) within a healthy population. The main question it aims to answer is: [1] Does VILPA yield effective outcomes? Throughout the course of the trial, participants will engage in a simulated regimen of vigorous intermittent lifestyle physical activity for a duration of 8 weeks. The efficacy of the exercise protocol will be quantified and evaluated through the utilization of a wearable device.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: September 1, 2023
• Est. primary completion date: July 10, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Healthy Adults

2. No exercise habits (more than 3 months)

Exclusion Criteria:

1. Exercising = 3 times per week;

2. the presence of chronic diseases, such as hypertension, hyperglycemic states, etc;

3. have conducted an exercise program in the past three months.

Related Conditions & MeSH terms

• Activity, Motor
• Health Behavior

Intervention

Other:
• Vigorous intermittent lifestyle physical activity
The specific exercise regimen involves performing rope jumping activities three times a day, with each session aimed at surpassing the exercise threshold (not conducted in a continuous manner), where the heart rate should exceed 160 beats per minute. This routine will be undertaken five times a week, continuously for a span of 8 weeks.

Locations

Country	Name	City	State
China	Guangdong Pharmaceutical University	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Xiao-dong Zhuang

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Isometric Strength Test	Isokinetic muscle strength testing with the Isomed 2000	15 minutes
Primary	Surface electromyography		30 minutes
Primary	Exercise Flat Test	cardiopulmonary function	30 minutes
Secondary	Fasting glucose		5 minutes
Secondary	Blood lipid		5 minutes